120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于胰岛素抵抗相关基因构建预测TACE反应的预后模型并识别PD-98059作为潜在治疗药物
Authors Wang W, Chen K, Fan C, Sun L, Tang H, Ding W, Sun F, Wang W
Received 14 July 2025
Accepted for publication 3 January 2026
Published 21 January 2026 Volume 2026:13 553710
DOI https://doi.org/10.2147/JHC.S553710
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Hop Tran Cao
Weitao Wang,* Kang Chen,* Chen Fan, Lei Sun, Haohuan Tang, Wei Ding, Feihu Sun, Weidong Wang
Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Feihu Sun, Email 907822062@qq.com Weidong Wang, Email Wdoc@sina.com
Purpose: Transarterial chemoembolization (TACE) is the primary treatment for unresectable hepatocellular carcinoma (HCC). Given the poor prognosis of liver cancer patients with diabetes, identifying indicators of response to TACE and methods to reverse non-response is crucial.
Methods: Patients were classified as TACE-responsive or non-responsive in the GSE104580 dataset. We conducted Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to identify the differentially expressed genes (DEGs). Univariate and multivariate Cox regression analyses were performed on genes in the insulin resistance signaling pathway to screen for those associated with poor prognosis in TACE. We developed a polygenic signature in GSE14520 using LASSO Cox regression, conducted molecular docking of four genes with drugs, and validated the results using drug sensitivity tests. The Connectivity Map (CMap) database was used to identify potential drugs for reversing TACE.
Results: We constructed a prognostic signature consisting of four genes (DUSP9, ENO2, NTS, and SERPINE1) and validated it using drug-sensitivity tests. Classifying TACE-treated patients into high- and low-risk groups using risk scores revealed that the high-risk group had significantly lower overall survival than the low-risk group. In patients undergoing TACE, the risk score independently predicted overall survival. Using the CMap database, we speculated that PD-98059 is a potential drug for reversing TACE unresponsiveness. We detected the docking sites of PD-98059 in four genes. Cell experiments confirmed that PD-98059 synergistically enhanced the inhibitory effect of lobaplatin on HCC cell proliferation.
Conclusion: The insulin resistance model tailored for TACE effectively predicts patient prognosis. Via the effect of MEK inhibitor PD-98059, the efficacy of TACE in patients can be improved.
Keywords: TACE, insulin resistance, prognosis, hepatocellular carcinoma, molecular docking, chemotherapy
Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Feihu Sun, Email 907822062@qq.com Weidong Wang, Email Wdoc@sina.com
Purpose: Transarterial chemoembolization (TACE) is the primary treatment for unresectable hepatocellular carcinoma (HCC). Given the poor prognosis of liver cancer patients with diabetes, identifying indicators of response to TACE and methods to reverse non-response is crucial.
Methods: Patients were classified as TACE-responsive or non-responsive in the GSE104580 dataset. We conducted Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to identify the differentially expressed genes (DEGs). Univariate and multivariate Cox regression analyses were performed on genes in the insulin resistance signaling pathway to screen for those associated with poor prognosis in TACE. We developed a polygenic signature in GSE14520 using LASSO Cox regression, conducted molecular docking of four genes with drugs, and validated the results using drug sensitivity tests. The Connectivity Map (CMap) database was used to identify potential drugs for reversing TACE.
Results: We constructed a prognostic signature consisting of four genes (DUSP9, ENO2, NTS, and SERPINE1) and validated it using drug-sensitivity tests. Classifying TACE-treated patients into high- and low-risk groups using risk scores revealed that the high-risk group had significantly lower overall survival than the low-risk group. In patients undergoing TACE, the risk score independently predicted overall survival. Using the CMap database, we speculated that PD-98059 is a potential drug for reversing TACE unresponsiveness. We detected the docking sites of PD-98059 in four genes. Cell experiments confirmed that PD-98059 synergistically enhanced the inhibitory effect of lobaplatin on HCC cell proliferation.
Conclusion: The insulin resistance model tailored for TACE effectively predicts patient prognosis. Via the effect of MEK inhibitor PD-98059, the efficacy of TACE in patients can be improved.
Keywords: TACE, insulin resistance, prognosis, hepatocellular carcinoma, molecular docking, chemotherapy